建龍微納(688357.SH):擬在泰國設子公司建相關項目 達產後可實現年產1.2萬噸多系列成型分子篩
格隆匯3月6日丨建龍微納(688357.SH)公佈,為適應國際化競爭需要,減輕對外貿易摩擦的影響,進一步推動公司產品和服務的國際化進程,公司計劃與全資子公司洛陽健陽科技有限公司、李羅僕在泰國設立子公司建設“洛陽建龍微納新材料股份有限公司泰國子公司建設項目”,註冊資本4.4億泰銖(按截至2020年3月3日匯率約合人民幣9728萬元),公司與全資子公司洛陽健陽科技有限公司的出資比例分別為99.9996%與0.0002%,李羅僕代公司出資0.0002%,公司直接和間接持有泰國子公司100%股權。公司擬使用超募資金9223.72萬元,不足部分由公司自籌資金補足。此次設立泰國子公司的對外投資行為不屬於關聯交易事項,未達到重大資產重組標準,不屬於重大資產重組事項。
項目建設內容:主要包括生產裝置、輔助建築工程、公用工程項目,達產後可實現年產12000噸多系列成型分子篩,其中:年產3A系列分子篩2000噸;4A系列分子篩4500噸;5A系列分子篩500噸;13X球形系列分子篩5000噸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.